Intensity Therapeutics resumes clinical trials, pursues partners for INT230-6

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. AAPL
5. NUE
6. AZN
7. TRMD
8. RARE
9. RTB
10. INTU

Go back to Intensity Therapeutics resumes clinical trials, pursues partners for INT230-6
(NASDAQ: INTS) Delayed: 3.90 +0.02 (0.52%)
Previous Close $3.88    52 Week High $ 
Open $3.79    52 Week Low $ 
Day High $3.93    P/E N/A 
Day Low $3.79    EPS $ 
Volume 7,232